Dermatoscopy

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
Thursday, February 22, 2024
Health, Other Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Therapy, Skin cancer, Neoplasm, Recurrence, Melasma, Scar, Toxicity, Melanocyte, FDA, SKS, Skin, Dermatoscopy, BCC, Entrepreneurship, Hyperpigmentation, Risk, Epidermis, Safety, PLA, Patient, Carcinoma, Laser, Medical imaging

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

DermaSensor Presents Study Results on Melanoma Detection in a Medicare Population at American Dermoscopy Meeting

Retrieved on: 
Thursday, July 13, 2023
Science, Biotechnology, Research, Oncology, Health, FDA, Medical Devices, Health Technology, Survival rate, DERM, Melanoma, UC Davis School of Medicine, CMS, Dermatoscopy, University, PCP, Centers for Medicare & Medicaid Services, Skin cancer, Cancer, Yale School of Medicine, Medicare, Therapy, Dermatology, UC, Patient, Lymph, Risk, Disease, Mortality, Hospital, Skin, Pharmaceutical industry, Medical imaging, Brigham

“In the hands of PCPs, I expect the DermaSensor device to help improve the detection of melanoma.

Key Points: 
  • “In the hands of PCPs, I expect the DermaSensor device to help improve the detection of melanoma.
  • This would result in improved, accelerated referrals to dermatologists, and that could save many Medicare patients’ lives."
  • The device was granted FDA Breakthrough Device designation and is currently under review by the FDA.
  • “With compelling clinical evidence in a Medicare population and FDA-breakthrough indication, DermaSensor plans to work directly with the Centers for Medicare & Medicaid Services (CMS) to explore how we can make our skin cancer detection technology accessible to Medicare patients,” said DermaSensor’s CEO, Cody Simmons.

Chapel Hill, NC dermatologist Dr. Beth Goldstein Selected as a NewBeauty Top Doctor

Retrieved on: 
Wednesday, July 5, 2023
Partnership, Skin cancer, Triangle, Dermatology, Laser, Publication, Beauty, MD, Patient safety, Dermatoscopy, Health, Veterinary medicine, Medical device

CHAPEL HILL, N.C., July 3, 2023 /PRNewswire/ -- NewBeauty is thrilled to announce that Chapel Hill, NC board-certified dermatologist Beth Goldstein, MD has been selected as a 2023 NewBeauty Top Doctor. Dr. Goldstein has made significant contributions to cosmetic dermatology and is the founder of Modern Ritual, a rapid tele-dermatology and dermoscopy platform designed to improve patient outcomes for general dermatologic conditions and detect skin cancer early.

Key Points: 
  • CHAPEL HILL, N.C., July 3, 2023 /PRNewswire/ -- NewBeauty is thrilled to announce that Chapel Hill, NC board-certified dermatologist Beth Goldstein, MD has been selected as a 2023 NewBeauty Top Doctor.
  • As a leading beauty authority, NewBeauty is committed to providing readers with accurate information from board-certified aesthetic experts.
  • This partnership with Dr. Goldstein highlights her outstanding work and dedication to patient safety, core values of the NewBeauty brand.
  • We are honored to have Dr. Goldstein as a NewBeauty Top Doctor and look forward to continuing to work together to provide readers with the most up-to-date and accurate information in the field of cosmetic dermatology.

Discovery of Distinctive Set of Gene Expression Patterns Changes Understanding of Atypical Mole Development and Early Melanoma

Retrieved on: 
Tuesday, June 20, 2023
Melanoma, University of California, San Diego, University, Physician, Skin cancer, Moles, Gene expression, Cell, RNA, Protein, American Journal, Extracellular matrix, Integrin, Dermatoscopy, Diagnosis, LOS, ECM, FDA, The American Journal of Pathology, Gene, Skin, Fibroblast, Medical imaging, Vaccine, Pathology

But many experts believe these do not progress to melanoma, based on evidence that only 30% of melanomas are associated with common moles.

Key Points: 
  • But many experts believe these do not progress to melanoma, based on evidence that only 30% of melanomas are associated with common moles.
  • However, the newly published analysis shows that dysplastic nevi are more similar to melanoma than previously believed and may contain genetic changes that can support the transition to melanoma.
  • These cells and proteins assist in the development of early melanoma, as well as the immune surveillance process that plays a substantial role at this early stage."
  • To develop into melanoma, dysplastic nevi must undergo genetic changes while also receiving various means of support from the surrounding tissue.

Codex Labs Introduces Integrative Medical Advisory Board

Retrieved on: 
Thursday, May 25, 2023
University, Pediatrics, Skin, Melasma, Alternative medicine, California State University, University of California, Davis, Ageing, Skin cancer, Quality of life, Northwestern, AP, Research, Mindfulness, Associate, Psoriasis, Inflammation, Silicon, Chicago, RNCP, MAB, Dermatoscopy, Vitiligo, Northwestern University, Jan Vansina, Pharmaceutical industry, Fine chemical, Medical device, Dermatology, MD, Ayurveda

San Jose, CA, May 25, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, announced an expanded medical advisory board (MAB) to support its focus on integrative skin-gut-brain solutions.

Key Points: 
  • San Jose, CA, May 25, 2023 (GLOBE NEWSWIRE) -- Codex Labs, a Silicon Valley bio-skintech company, announced an expanded medical advisory board (MAB) to support its focus on integrative skin-gut-brain solutions.
  • The Chairman of the MAB is Dr. Raja Sivamani, MD MS AP, is an integrative dermatologist, bioengineer, and Ayurvedic practitioner.
  • He is the founding director of the Chicago Integrative Eczema Center and a board member of the National Eczema Association.
  • She is also board certified in Integrative Medicine and Lifestyle Medicine, and is active on the American Board of Integrative Medicine.

Androgenetic Alopecia Epidemiology Forecast 2023 -2032 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 14, 2023
Health, Other Health, History, Woman, Biopsy, Pattern hair loss, United Kingdom, Dutasteride, Classification, Scalp, Loss, Puberty, SME, Hair, Dermatoscopy, Epidemiology, Head, Platelet-rich plasma, Hair loss, EU4, Patient, Androgen, Cyproterone acetate, Food, Diagnosis, Spironolactone, FDA, Finasteride, Risk, Male, US Foods, Vaccine, Generic drug, Dentistry, Management, Pharmaceutical industry, Nursing

This 'Androgenetic Alopecia - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of androgenetic alopecia in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom and Japan.

Key Points: 
  • This 'Androgenetic Alopecia - Epidemiology Forecast - 2032' report delivers an in-depth understanding of the historical and forecasted epidemiology of androgenetic alopecia in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom and Japan.
  • The disease epidemiology covered in the report provides historical and forecasted androgenetic alopecia epidemiology segmented as the total prevalent cases of androgenetic alopecia, total prevalent cases of androgenetic alopecia in males, total prevalent cases of androgenetic alopecia in females, total diagnosed prevalent cases of androgenetic alopecia in males and total diagnosed prevalent cases of androgenetic alopecia in females.
  • The report describes Androgenetic Alopecia epidemiology by the number of patients developing androgenetic alopecia in the 7MM.
  • The report describes the androgenetic alopecia epidemiology by the type-specific cases of androgenetic alopecia patients in the 7MM.

SciBase Interim report

Retrieved on: 
Thursday, November 10, 2022
CH, Stanford University, Health, Annual, SIAF, Collaboration, Mouse, Electrode, Nature, EIS, SE, Skin, Detergent, Dermatoscopy, FDA, Electric battery, Medical device

Electrode sales volume increased by 39% and reached 30,172 (21,768) units.

Key Points: 
  • Electrode sales volume increased by 39% and reached 30,172 (21,768) units.
  • FDA expert panel in line with SciBase position to keep stringent approval level for all new skin lesion analyzers in the US.
  • The study, which is not yet published, was performed by SIAF (CH), CK-CARE (CH), SciBase (SE) and the Sean N. Parker Allergy and Asthma research institute at Stanford (US).
  • Collaboration agreement signed with Johnson & Johnson Consumer Health to develop a skin barrier screening product for infants.

New study shows Nevisense significantly improves US clinician's decision-making beyond dermoscopy

Retrieved on: 
Wednesday, October 26, 2022
EIS, Standard of care, Publication, Skin, Melanoma, Technology, Decision-making, Trial of the century, Cancer, PSL, Melanoma Research, CEO, Dermatoscopy, Biopsy, Research, Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai, Medical imaging

The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research".

Key Points: 
  • The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research".
  • The study included 231 US Dermatologists making a total of 33.957 biopsy decisions.
  • The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result.
  • As expected, the study showed that dermoscopy improved decision making over naked eye assessment, but more importantly it showed that using Nevisense further improved clinician performance by at least as much again.

New study shows Nevisense significantly improves US clinician's decision-making beyond dermoscopy

Retrieved on: 
Wednesday, October 26, 2022
EIS, Standard of care, Publication, Skin, Melanoma, Technology, Decision-making, Trial of the century, Cancer, PSL, Melanoma Research, CEO, Dermatoscopy, Biopsy, Research, Dermatology, Icahn School of Medicine at Mount Sinai, Mount Sinai, Medical imaging

The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research".

Key Points: 
  • The article named "Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy" has been published in the journal "Melanoma Research".
  • The study included 231 US Dermatologists making a total of 33.957 biopsy decisions.
  • The study participants showed a statistically significant improvement in correct biopsy decisions beyond their dermoscopic evaluation when integrating the Nevisense result.
  • As expected, the study showed that dermoscopy improved decision making over naked eye assessment, but more importantly it showed that using Nevisense further improved clinician performance by at least as much again.

Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022
Oncology, Health, Medical Devices, Genetics, Research, Science, Biotechnology, LinkedIn, Uncertainty, Securities Act of 1933, Dermatology, Risk, SEC, Diagnosis, Patient, List of life sciences, Twitter, Instagram, Annual general meeting, Nasdaq, Malignancy, Company, Health, Atopic dermatitis, Skin, Dermatoscopy, Securities Exchange Act of 1934, Castle, College, GEP, Uveal melanoma, Medical imaging, Facebook

In the case study presented during the College of American Pathologists 2022 (CAP22) Annual Meeting, DiffDx-Melanoma supported the need to perform a local excision on a difficult-to-diagnose melanocytic lesion after clinicopathological correlation was not achieved by dermoscopy, reflectance confocal microscopy and/or histopathological assessment alone.

Key Points: 
  • In the case study presented during the College of American Pathologists 2022 (CAP22) Annual Meeting, DiffDx-Melanoma supported the need to perform a local excision on a difficult-to-diagnose melanocytic lesion after clinicopathological correlation was not achieved by dermoscopy, reflectance confocal microscopy and/or histopathological assessment alone.
  • Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care.
  • DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath Melanoma, DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
  • The word can and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.